Abstract
Aiming to improve the effector function of CAR-T cells, Zhao etal.1 report that IL-10 metabolically reprograms CAR-T cells, and this promotes their effectiveness against solid tumors and challenges IL-10's perceived role as merely immunosuppressive. This simple but promising strategy fosters durable immune memory and eagerly awaits validation in clinical trials.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
